铁氧还蛋白1(FDX1)是铜死亡(cuproptosis)的关键调控基因，参与肿瘤细胞和免疫微环境中多种代谢过程，在肿瘤治疗和生存预后等方面发挥着重要作用。本综述通过研究FDX1影响细胞发生铜死亡的功能和分子机制，分析FDX1与泛癌中患者生存预后关系、FDX1与肿瘤免疫和药物敏感性的联系，发现FDX1参与调控线粒体功能、调节肿瘤细胞内铜离子平衡、影响肿瘤细胞铜死亡，并且FDX1与肿瘤患者的预后、免疫细胞浸润、肿瘤免疫应答和肿瘤耐药紧密相关。因此，FDX1可为开发肿瘤新的潜在治疗靶点、免疫治疗反应的指标和预后标志物提供新的思路。

[1] TSVETKOV P,COY S,PETROVA B,et al.Copper induces cell death by targeting lipoylated TCA cycle proteins[J].Science,2022,375(6586):1254-1261.
[2] SCHULZ V,BASU S,FREIBERT S A,et al.Functional spectrum and specificity of mitochondrial ferredoxins FDX1 and FDX2[J].Nat Chem Biol,2023,19(2):206-217.
[3] GUENGERICH F P.Cytochrome P450 research and The Journal of Biological Chemistry[J].J Biol Chem,2019,294(5):1671-1680.
[4] CHILIZA Z E,MARTÍNEZ-OYANEDEL J,SYED K.An overview of the factors playing a role in cytochrome P450 monooxygenase and ferredoxin interactions[J].Biophys Rev,2020,12(5):1217-1222.
[5] SHEFTEL A D,STEHLING O,PIERIK A J,et al.Humans possess two mitochondrial ferredoxins,Fdx1 and Fdx2,with distinct roles in steroidogenesis,heme,and Fe/S cluster biosynthesis[J].Proc Natl Acad Sci U S A,2010,107(26):11775-11780.
[6] CAI K,TONELLI M,FREDERICK R O,et al.Human mitochondrial ferredoxin 1(FDX1) and ferredoxin 2(FDX2) both bind cysteine desulfurase and donate electrons for iron-sulfur cluster biosynthesis[J].Biochemistry,2017,56(3):487-499.
[7] TSVETKOV P,DETAPPE A,CAI K,et al.Mitochondrial metabolism promotes adaptation to proteotoxic stress[J].Nat Chem Biol,2019,15(7):681-689.
[8] 王映翘,杨密,王茵,等.铜及铜相关蛋白在肿瘤中的研究进展[J].肿瘤代谢与营养电子杂志,2022,9(2):265-270.
[9] WANG Y,ZHANG L,ZHOU F.Cuproptosis:a new form of programmed cell death[J].Cell Mol Immunol,2022,19(8):867-868.
[10] TANG D,CHEN X,KROEMER G.Cuproptosis:a copper-triggered modality of mitochondrial cell death[J].Cell Res,2022,32(5):417-418.
[11] GE E J,BUSH A I,CASINI A,et al.Connecting copper and cancer:from transition metal signalling to metalloplasia[J].Nat Rev Cancer,2022,22(2):102-113.
[12] LI X,DAI Z,LIU J,et al.Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer[J].Front Genet,2022,13:969856.
[13] WANG L,CAO Y,GUO W,et al.High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma(COAD)[J].J Cancer Res Clin Oncol,2023,149(1):15-24.
[14] YANG W,WANG Y,HUANG Y,et al.4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer[J].Biomed Pharmacother,2023,159:114301.
[15] ZHANG Z,MA Y,GUO X,et al.FDX1 can impact the prognosis and mediate the metabolism of lung adenocarcinoma[J].Front Pharmacol,2021,12:749134.
[16] HUANG X,WANG T,YE J,et al.FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis[J].Front Genet,2022,13:994741.
[17] YAO Y,CHEN H,LOU M,et al.Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration[J].Front Genet,2023,14:1071694.
[18] ZHANG C,ZENG Y,GUO X,et al.Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker[J].Front Genet,2022,13:923737.
[19] WANG Y,ZHANG X,CHEN G,et al.Integrated analyses reveal the prognostic,immunological features and mechanisms of cuproptosis critical mediator gene FDX1 in KIRC[J].Genes Immun,2023,24(4):171-182.
[20] XU J,HU Z,CAO H,et al.Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma[J].Front Immunol,2022,13:981764.
[21] XIE M,CHENG B,YU S,et al.Cuproptosis-related MiR-21-5p/FDX1 axis in clear cell renal cell carcinoma and its potential impact on tumor microenvironment[J].Cells,2022,12(1):173.
[22] ZHANG Z,ZENG X,WU Y,et al.Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in hepatocellular carcinoma[J].Front Immunol,2022,13:925618.
[23] QUAN Y,LI W,YAN R,et al.Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1[J].Front Oncol,2023,13:1168769.
[24] WANG T,LIU Y,LI Q,et al.Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma[J].Front Immunol,2022,13:999823.
[25] YANG L,ZHANG Y,WANG Y,et al.Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity:a pan-cancer analysis[J].Front Pharmacol,2022,13:938134.
[26] MLECNIK B,BIFULCO C,BINDEA G,et al.Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage Ⅲ colon cancer[J].J Clin Oncol,2020,38(31):3638-3651.
[27] MLECNIK B,LUGLI A,BINDEA G,et al.Multicenter international study of the consensus immunoscore for the prediction of relapse and survival in early-stage colon cancer[J].Cancers(Basel),2023,15(2):148.
[28] KLUTSTEIN M,NEJMAN D,GREENFIELD R,et al.DNA methylation in cancer and aging[J].Cancer Res,2016,76(12):3446-3450.
[29] ZHAO B S,ROUNDTREE I A,HE C.Post-transcriptional gene regulation by mRNA modifications[J].Nat Rev Mol Cell Biol,2017,18(1):31-42.
[30] PICARD E,VERSCHOOR C P,MA G W,et al.Relationships between immune landscapes,genetic subtypes and responses to immunotherapy in colorectal cancer[J].Front Immunol,2020,11:369.
[31] LIU Z,MIAO J.Prognostic and immunological role of FDX1 in pan-cancer:an in-silico analysis[J].Sci Rep,2023,13(1):7926.
[32] LU H,LIANG J,HE X,et al.A novel oncogenic role of FDX1 in human melanoma related to PD-L1 immune checkpoint[J].Int J Mol Sci,2023,24(11):9182.
[33] 苏厦露,麻发强,金风.放射治疗与靶向治疗或免疫治疗联合治疗头颈部鳞癌的研究进展[J].现代医学,2023,51(12):1778-1783.
[34] XIAO C,YANG L,JIN L,et al.Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer[J].Front Genet,2022,13:962028.